Isavuconazole to prevent invasive fungal infection in immunocompromised adults: Initial experience at an academic medical centre
| Autor: | James S. Lewis, Christina D. Bowen, Morgan Hakki, Gregory B Tallman |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
0301 basic medicine
Drug Adult Male medicine.medical_specialty Posaconazole Early discontinuation Antifungal Agents Pyridines media_common.quotation_subject Cost-Benefit Analysis 030106 microbiology Dermatology Chemoprevention 030207 dermatology & venereal diseases 03 medical and health sciences Immunocompromised Host Oregon 0302 clinical medicine Refractory Risk Factors Internal medicine Nitriles medicine Humans Clinical efficacy Formulary media_common Retrospective Studies Academic Medical Centers Inpatients business.industry Drug cost General Medicine Middle Aged Triazoles Infectious Diseases Female business Invasive Fungal Infections medicine.drug Cohort study |
| Zdroj: | Mycoses. 62(8) |
| ISSN: | 1439-0507 |
| Popis: | OBJECTIVE To evaluate clinical and economic outcomes associated with the use of isavuconazole as antifungal prophylaxis in high-risk immunocompromised patients. PATIENTS/METHODS Retrospective, single-centre cohort study of patients who received isavuconazole prophylaxis. Outcomes assessed included breakthrough IFI, early discontinuation of isavuconazole for any reason and antifungal prophylaxis prescribed at discharge. The impact on inpatient drug expenditure was evaluated using current isavuconazole and posaconazole drug costs per observed isavuconazole days of therapy (DOT) during the study period. RESULTS One hundred thirty-eight courses of isavuconazole prophylaxis were administered to 98 inpatients (2193 DOT). Relapsed/refractory acute myelogenous leukaemia was the indication for prophylaxis in over half (59.4%) of patients. Breakthrough IFI occurred in 8 (5.8%) courses. Suspected drug-related toxicities led to early discontinuation in 6 (4.3%) courses (five hepatotoxicity, one drug rash). At discharge, 24 (17.4%) courses lacked insurance coverage for isavuconazole. The formulary switch to isavuconazole prophylaxis resulted in an estimated mean drug cost savings of $128.25 per DOT relative to estimated posaconazole costs (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text